METABIOTICS

PRESENT STATE, CHALLENGES AND PERSPECTIVES
1. Auflage 2020
ISBN: 978-3-030-34169-5
Verlag: Springer International Publishing

Buch, Englisch, 123 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 219 g

Aimed at students, researchers, nutritionists, and developers in food technology, this research text addresses the nascent field of metabiotics. Metabiotics are products based on components of cells, metabolites, and signaling molecules released by probiotic strains, engineered to optimize host-specific physiological functions in a way that traditional probiotics cannot. This book examines the history, processes, design, classifications, and functions of metabiotics. It includes an overview of the composition and function of the gut microbiota, and discusses development of target-specific metabiotics. Further coverage includes comparisons to traditional probiotics, as well as probiotic safety and side-effects.  provides a complete history and understanding of this new field, the next phase of the probiotic industry.

Zielgruppe

Research

Autoren/Hrsg.

Shenderov, Boris A.

Lang, Christine

Sinitsa, Alexander V.

Zakharchenko, Mikhail M.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie
• Naturwissenschaften Chemie Analytische Chemie Umweltchemie, Lebensmittelchemie
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Ökotrophologie (Ernährungs- und Haushaltswissenschaften)
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Lebensmitteltechnologie und Getränketechnologie
• Naturwissenschaften Biowissenschaften Zellbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Medizinische Mikrobiologie & Virologie

Inhaltsverzeichnis

Ch 1: Introduction.- Ch 2: The composition and functions of the human gut symbiotic microbiota.- Ch 3: Contemporary views on biotechnological potential of symbiotic microorganisms.- Ch 4: The digestive function of human gut microbiota.- Ch 5: Metabolic relationship between the host and its gut microbiota.- Ch 6: Factors and agents that modify the composition and functions of symbiotic microbiota, diagnostic methods for microecological imbalance and its consequences.- Ch 7: Contemporary microecological strategies of gut microbiota modulating for human health preservation, restoration and improvement.- Ch 8: Molecular language of symbiotic gut microorganisms.- Ch 9: Drawbacks and negative consequences of traditional probiotics based on live microorganisms.- Ch 10: Metabiotics, New stage of the probiotic concept development.- Ch 11: Methods and techniques used for obtaining and identifying of microbial low molecular weight cellular compounds, metabolites and signaling molecules.- Ch 12: Classification of metabiotics and their brief description.- Ch 13: Some of the best-known metabiotics on the market of microecological market.- Ch 14: Cellular metabiotics and Metabolite metabiotics.- Ch 15: Prospects in the field of intended-use metabiotics creation.- Ch 16: Some new targets and approaches to the construction of intended-use metabiotics.- Ch 17: Conclusion.

Über Autor(innen)

Boris A. Shenderov is a physician, Doctor of Medical Science (1976), Professor of Microbiology (1979), Active Member of New-York Academy of Science (1996). Professor of Scientific Research Laboratory "Design and implementation of personal nutrition products and rations" of K.G. Razumovsky Moscow State University of Technology and Management; Professor of Interdisciplinary Neurology Department of Institute of Interdisciplinary Medicine, Moscow, Russia (2018 up to now). His main research interest is Medical Microbial Ecology; Genetics, Epigenetic, Metabolomic, Probiotics; Metabiotics,Functional Foods; Biotechnology. He is an author of more 550 scientific papers, including 12 books, 30 inventions. He was the Director of Moscow Research Institute of Epidemiology and Microbiology after Gabrichevsky G.N. (MRIEM), Ministry of Public Health, Russian Federation (1998-2004); President of Russian Yogurt corp., Moscow Russia (2004-2010); Main Researcher of MRIEM (2010-2018).He was a councilor of Executive Board of International Society of Microbial Ecology and Disease (SOMED) (2008-2013); a Member of Executive Board and President of International Society of Gnotobiology (IAG) (2008-2014), a Member of Russian Society of Microbiology and Epidemiology after I. Mechnikov; member of Editorial Boards of five Russian Science Journals & International J “Microbial Ecology and Health Diseases”(up to now). 

Alexander V. Sinitsa Candidate of Technical Sciences, President “Kraft”, Saint-Petersburg, Russia. His main scientific interest is Probiotics, Prebiotics, Metabiotics (Postbiotics), Functional Foods, Sports Nutrition. He is an author and co-author of more than 100 scientific papers. He heads the company, one of the leaders in the development of metabiotics in Russia. 

Mikhail M. Zakharchenko is a physician, Candidate of Medical Science (2003), Head of R&D Department of “Kraft”, Saint-Petersburg, Russia. His main scientific interest is Microbiome, Probiotics, Prebiotics, Metabiotics (Postbiotics), Functional Foods. He is an author and co-author of more than 100 scientific papers. A Member of Executive Board of Scientific Conferences ”Prenosology” (2005-2019). Member of Editorial Board of Russian Science Journal «Prenosology and Healthy Lifestyle» (2007-2019). He leads the development of new metabiotics at «Kraft». 

Christine Lang Prof. Dr. is an entrepreneur in biotechnology; she acts as a consultant for the German government for bioeconomy topics and co-chairs the German Bioeconomy Council. She is an Associate Professor for Microbiology and Molecular Genetics at Technical University Berlin and president of the German Association of General and Applied Microbiology (VAAM). In 2001 Ms Lang founded the company Organobalance GmbH and established it as an R&D facility to develop novel microbial active ingredients and strains for food, feed, personal care and pharma applications. Since September 2016, Organobalance is a part ofNovozymes A/S. Till June 2018, she was the company’s CEO and she now serves as a consultant for Novozymes A/S. Christine Lang is co-founder and partner of BELANO medical AG focused on production and sales of microbiotic products for human health.